Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.1
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 12271141
Tee AR, et al. (2002) Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A 99, 13571-6 12271141
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T37-p - 4E-BP1 (human)
Modsite: PPGDysttPGGtLFs SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T37‑p, 4E‑BP1 (mouse): T36‑p, 4E‑BP1 (rat): T36‑p, 4E‑BP1 (fruit fly): T37‑p, 4E‑BP1 (cow): T37‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293E (epithelial), U2OS (bone cell) [GR (human)]
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin inhibit treatment-induced increase

T46-p - 4E-BP1 (human)
Modsite: GGtLFsttPGGtRII SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T46‑p, 4E‑BP1 (mouse): T45‑p, 4E‑BP1 (rat): T45‑p, 4E‑BP1 (fruit fly): T46‑p, 4E‑BP1 (cow): T46‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293E (epithelial), U2OS (bone cell) [GR (human)]
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin inhibit treatment-induced increase

S65-p - 4E-BP1 (human)
Modsite: FLMECrNsPVtktPP SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): S65‑p, 4E‑BP1 (mouse): S64‑p, 4E‑BP1 (rat): S64‑p, 4E‑BP1 (fruit fly): S65‑p, 4E‑BP1 (cow): S65‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293E (epithelial), U2OS (bone cell) [GR (human)]
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin inhibit treatment-induced increase

T70-p - 4E-BP1 (human)
Modsite: rNsPVtktPPRDLPt SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T70‑p, 4E‑BP1 (mouse): T69‑p, 4E‑BP1 (rat): T69‑p, 4E‑BP1 (fruit fly): T70‑p, 4E‑BP1 (cow): T70‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293E (epithelial), U2OS (bone cell) [GR (human)]
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin inhibit treatment-induced increase

T308-p - Akt1 (human)
Modsite: kDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293E (epithelial), U2OS (bone cell) [GR (human)]
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin no effect upon treatment-induced increase
wortmannin insulin inhibit treatment-induced increase
phorbol_ester no change compared to control
amino_acids no change compared to control

T1462-p - TSC2 (human)
Modsite: GLRPRGytISDsAPs SwissProt Entrez-Gene
Orthologous residues
TSC2 (human): T1462‑p, TSC2 iso2 (human): T1419‑p, TSC2 iso3 (human): T1418‑p, TSC2 iso4 (human): T1439‑p, TSC2 (mouse): T1465‑p, TSC2 iso6 (mouse): T1443‑p, TSC2 (rat): T1466‑p, TSC2 iso2 (rat): T1423‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293E (epithelial), U2OS (bone cell) [GR (human)]
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase